Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review.
Saved in:
| Title: | Management of splenomegaly in patients with myelofibrosis in the era of JAK inhibitors: a comprehensive review. |
|---|---|
| Authors: | Al-Asa'd Y; Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar., Qasem N; Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar., Alshurafa A; Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar., Al-Farsi K; Hematology Department, National Hematology and Bone Marrow Transplant Center, University Medical City, Muscat, Oman., Yassin MA; Department of Hematology, National Center for Cancer Care and Research (NCCCR), Hamad Medical Corporation, Doha, Qatar.; College of Medicine, Qatar University, Doha, Qatar. |
| Source: | Frontiers in oncology [Front Oncol] 2026 May 20; Vol. 16, pp. 1851781. Date of Electronic Publication: 2026 May 20 (Print Publication: 2026). |
| Publication Type: | Journal Article; Review |
| Journal Info: | Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101568867 Publication Model: eCollection Cited Medium: Print ISSN: 2234-943X (Print) Linking ISSN: 2234943X NLM ISO Abbreviation: Front Oncol Subsets: PubMed not MEDLINE |
| Database: | MEDLINE Ultimate |
|
Full text is not displayed to guests.
Login for full access.
|
|
| ISSN: | 2234-943X |
|---|---|
| DOI: | 10.3389/fonc.2026.1851781 |
